跳至主要内容
临床试验/IRCT20140818018842N27
IRCT20140818018842N27已完成3 期

A study to evaluate the efficacy of Atorvastatin in the prophylaxis of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT)

Tehran University of Medical Sciences0 个研究点目标入组 75 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Donor age : 18 years or above
  • Normal liver function in donors
  • Normal renal function in recipients
  • KPS =>60 for donors
  • Patients with a history of hematologic malignancies or bone marrow failure syndromes
  • Recipient age: 18 to 60 years
  • A fully HLA-matched family donor
  • LVEF=>40% for recipients
  • Normal liver function in recipients
  • Normal renal function in donors
  • KPS =>70 for recipients
  • There is no no prohibition for patients who already received Atorvastatin

排除标准

  • Pregnant women and lactating mothers
  • Positive history of hypersensitivity to Atorvastatin in donors
  • HIV-positive donors
  • HIV-positive recipients
  • Positive history of hypersensitivity to Atorvastatin in recipients
  • Patients receiving ATG

研究者

相似试验

A study to evaluate the effect of Atorvastatin in... | 临床试验